Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Short Interest Update

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) was the recipient of a large decline in short interest in March. As of March 31st, there was short interest totaling 42,958 shares, a decline of 24.6% from the March 15th total of 56,970 shares. Currently, 4.4% of the shares of the stock are short sold. Based on an average daily volume of 20,152 shares, the short-interest ratio is currently 2.1 days.

Bluejay Diagnostics Stock Performance

NASDAQ BJDX opened at $1.86 on Wednesday. Bluejay Diagnostics has a 52-week low of $1.65 and a 52-week high of $16.68. The company has a market capitalization of $1.80 million, a P/E ratio of 0.00 and a beta of 0.67. The company has a fifty day moving average of $2.16 and a 200-day moving average of $4.36.

Bluejay Diagnostics (NASDAQ:BJDX) last posted its quarterly earnings data on Friday, March 6th. The company reported $3.23 earnings per share (EPS) for the quarter.

Institutional Trading of Bluejay Diagnostics

An institutional investor recently bought a new position in Bluejay Diagnostics stock. Armistice Capital LLC purchased a new position in Bluejay Diagnostics, Inc. (NASDAQ:BJDX) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned about 9.15% of Bluejay Diagnostics as of its most recent SEC filing. Institutional investors own 18.47% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Bluejay Diagnostics in a research report on Friday, March 27th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, Bluejay Diagnostics currently has a consensus rating of “Sell”.

Bluejay Diagnostics Company Profile

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.